Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(100.0%)
2Total
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02070133Phase 3Completed

Efficacy of Simvastatin for the Treatment of COPD

Role: collaborator

NCT01750658Completed

Study of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations In Spain

Role: lead

NCT01122758Unknown

Chronic Obstructive Pulmonary Disease (COPD) History Assessment In SpaiN (CHAIN)

Role: lead

NCT01374932Phase 3Unknown

CPASMA: Is There an Improvement in Asthma in Patients With Both Asthma and OSAS Treated With CPAP?

Role: lead

NCT00787748Completed

COPD and Cardiovascular Risk in the Population

Role: lead

NCT00904384Completed

Prevalence and Determinants of Chronic Obstructive Pulmonary Disease (COPD) in HIV+ Patients

Role: lead

All 6 trials loaded